Signet and Bayer in inflammatory disease pact
This article was originally published in Clinica
Executive Summary
US diagnostic/research firm Signet Laboratories has formed a pact with Bayer Diagnostics to conduct research into inflammatory-based diseases using the latter's urinary trypsin inhibitor immunoassays. The Dedham, Massachusetts firm has licensed the immunoassays, which were discovered by Bayer scientists and which detect two markers of inflammation, uristatin and bikunin, in blood and urine.